Ibrutinib: Difference between revisions
From IDWiki
mNo edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
* Bruton's tyrosine kinase inhibitor (important for B cell function) |
* Bruton's tyrosine kinase inhibitor (important for B cell function) |
||
* Used to treat CLL |
* Used to treat CLL |
||
* Can cause [[neutropenia]] |
|||
* Increased risk of invasive fungal infections, especially invasive [[aspergillosis]] (including CNS disease) [[CiteRef::ghez2018ea]] |
* Increased risk of pneumonia, [[UTI]], upper respiratory tract infection, and invasive fungal infections, especially invasive [[aspergillosis]] (including CNS disease) and also [[cryptococcosis]] [[CiteRef::ghez2018ea]] |
||
[[Category:Medications]] |
|||
[[Category:Oncology]] |
|||
[[Category:Hematology]] |
|||
Latest revision as of 17:49, 5 July 2024
- Bruton's tyrosine kinase inhibitor (important for B cell function)
- Used to treat CLL
- Can cause neutropenia
- Increased risk of pneumonia, UTI, upper respiratory tract infection, and invasive fungal infections, especially invasive aspergillosis (including CNS disease) and also cryptococcosis 1
References
- ^ David Ghez, Anne Calleja, Caroline Protin, Marine Baron, Marie-Pierre Ledoux, Gandhi Damaj, Mathieu Dupont, Brigitte Dreyfus, Emmanuelle Ferrant, Charles Herbaux, Kamel Laribi, Ronan Le Calloch, Marion Malphettes, Franciane Paul, Laetitia Souchet, Malgorzata Truchan-Graczyk, Karen Delavigne, Caroline Dartigeas, Loïc Ysebaert. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955-1959. doi:10.1182/blood-2017-11-818286.
